Osteopontin as a prognostic biomarker in head and neck cancer- a systematic review and meta-analysis.

Q3 Dentistry Evidence-based dentistry Pub Date : 2025-03-12 DOI:10.1038/s41432-025-01133-8

Nadisha Piyarathne, Kalani Hettiarachchi, Monal Yuwanati, Gowri Sivaramakrishnan, Anand Ramanathan, Ruwan Jayasinghe, Sanaa Chala, Akhilanand Chaurasia

{"title":"Osteopontin as a prognostic biomarker in head and neck cancer- a systematic review and meta-analysis.","authors":"Nadisha Piyarathne, Kalani Hettiarachchi, Monal Yuwanati, Gowri Sivaramakrishnan, Anand Ramanathan, Ruwan Jayasinghe, Sanaa Chala, Akhilanand Chaurasia","doi":"10.1038/s41432-025-01133-8","DOIUrl":null,"url":null,"abstract":"Background: Osteopontin (OPN) is linked to cancer progression, metastasis, and treatment resistance in head and neck cancer (HNC). This meta-analysis evaluated OPN as a prognostic biomarker in HNC.Method: A comprehensive search was conducted for studies published up to December 2023, including English papers on HNC analyzing OPN expression. Data extraction, quality assessment, and quantitative analysis were performed using fixed and random effect models with 95% CI. Heterogeneity and publication bias were assessed with I2 and Egger's regression test.Results: Fifty-one studies were included. OPN expression was significantly elevated in tissue and plasma in HNC compared to control (SMD 0.98; 95% CI 0.47-1.49; I2 = 13%; p < 0.00). High plasma OPN predicted poor survival (HR: 2.00; I2 = 64%; P = 0.03), as did high tissue OPN (hazard ratio: 2.71, 95% confidence interval = 1.51-4.87; I2 = 49.4%, p > 0.05). Elevated plasma OPN correlated with smoking, poorly differentiated neoplasms, larger tumors, advanced stage, and lymph node metastasis. Positive tissue OPN was associated with nodal involvement, advanced stage, male gender, and smoking.Conclusion: OPN is a robust prognostic biomarker in HNC, indicating tumor aggressiveness and poor prognostic outcomes. Standardized measurement protocols and further validation in prospective studies are necessary.","PeriodicalId":12234,"journal":{"name":"Evidence-based dentistry","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based dentistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s41432-025-01133-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Dentistry","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Osteopontin (OPN) is linked to cancer progression, metastasis, and treatment resistance in head and neck cancer (HNC). This meta-analysis evaluated OPN as a prognostic biomarker in HNC.

Method: A comprehensive search was conducted for studies published up to December 2023, including English papers on HNC analyzing OPN expression. Data extraction, quality assessment, and quantitative analysis were performed using fixed and random effect models with 95% CI. Heterogeneity and publication bias were assessed with I2 and Egger's regression test.

Results: Fifty-one studies were included. OPN expression was significantly elevated in tissue and plasma in HNC compared to control (SMD 0.98; 95% CI 0.47-1.49; I2 = 13%; p < 0.00). High plasma OPN predicted poor survival (HR: 2.00; I2 = 64%; P = 0.03), as did high tissue OPN (hazard ratio: 2.71, 95% confidence interval = 1.51-4.87; I2 = 49.4%, p > 0.05). Elevated plasma OPN correlated with smoking, poorly differentiated neoplasms, larger tumors, advanced stage, and lymph node metastasis. Positive tissue OPN was associated with nodal involvement, advanced stage, male gender, and smoking.

Conclusion: OPN is a robust prognostic biomarker in HNC, indicating tumor aggressiveness and poor prognostic outcomes. Standardized measurement protocols and further validation in prospective studies are necessary.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Evidence-based dentistry Dentistry-Dentistry (all)

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： Evidence-Based Dentistry delivers the best available evidence on the latest developments in oral health. We evaluate the evidence and provide guidance concerning the value of the author''s conclusions. We keep dentistry up to date with new approaches, exploring a wide range of the latest developments through an accessible expert commentary. Original papers and relevant publications are condensed into digestible summaries, drawing attention to the current methods and findings. We are a central resource for the most cutting edge and relevant issues concerning the evidence-based approach in dentistry today. Evidence-Based Dentistry is published by Springer Nature on behalf of the British Dental Association.